Introduction
============

Cardiovascular diseases (CVDs) are the number one killer of both men and women worldwide ([@B141]). Type 2 diabetes mellitus (T2DM) is an independent risk factor for CVD ([@B88]; [@B1]; [@B6]; [@B41]). Diabetic patients have a two- to fourfold increased risk for CVD development, and undoubtedly, the increased prevalence of T2DM has led to more documented cases of cardiovascular complications ([@B74]; [@B75]; [@B91]; [@B18]). Indeed, while T2DM contributes to overt CVD, it has been documented to be responsible for a unique set of cardiac abnormalities ([@B97]; [@B72]; [@B132]), referred to as diabetic cardiomyopathy. Several of the cellular mechanisms documented to underlie the development of contractile dysfunction in diabetic cardiomyopathy include: impaired excitation-contraction coupling, inefficient energy production, reduced coronary flow reserve, and fibrotic remodeling ([@B97]). Not surprising, many of these mechanisms are also observed in hypertrophic and dilated cardiomyopathies, independent of diabetes, promoting the equivocation and questioning a universal clinical definition for diabetic cardiomyopathy. In further support of the ambiguity, a review by [@B66] reported that "instead of being a cardiomyopathy in the classical sense though, diabetic cardiomyopathy represents a combination of molecular myocardial abnormalities that predispose for the development of myocardial dysfunction." Additional questions regarding diabetic cardiomyopathy and its progression in both insulin-dependent and insulin-independent diabetic patients remain unanswered. Although a ubiquitous definition has yet been agreed upon, diabetic cardiomyopathy is generally accepted to refer to diabetes-associated changes in the structure and function of the myocardium, independent of other peripheral disease, in otherwise healthy diabetic patients ([@B40]).

The first documented associations between diabetes mellitus and any cardiovascular complications appeared in the first half of the 20th century ([@B85]). However, the first reports of what we know today as "diabetic cardiomyopathy" did not appear until the early 1970s when it was documented that diabetic patients with congestive heart failure, who had no evidence of coronary atherosclerosis, had abnormal fibrosis patterns within the myocardium ([@B115]). Shortly after, the Framingham Study provided epidemiological data supporting the notion that a specific cardiomyopathy does exist in diabetics, and that cardiovascular mortality was threefold higher in participants with diabetes ([@B74]). In the ∼40 years since these seminal studies appeared, increased incidence of T2DM, CVD, and the complex interactions between them have underscored the need for a better understanding of the pathology and possible treatments. Beyond epidemiological and associative data describing diabetic cardiomyopathy, the basic science and general understanding of its progression, incidence, and possible treatment(s) remain in their infancy. Nevertheless, mounting evidence suggests that the incidence of diabetic cardiomyopathy is sex and age dependent ([@B78]).

The Framingham Heart Study first revealed that diabetic women have a 5.1-fold increase in heart failure, while diabetic men only have a 2.4-fold increase compared to non-diabetic women and men, respectively ([@B74]). Since that time, several studies provided similar evidence that diabetic women have a greater relative risk of CVD compared to diabetic men ([@B64]; [@B12]; [@B126]; [@B49]; [@B101]). [@B82] assessed gender differences in hospital admissions for major cardiovascular events in diabetics throughout England over 10 years between 2004 and 2014. They confirmed that diabetic women, compared to men, had increased hospital admission rates for acute myocardial incident (AMI), percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG). Specifically, compared to non-diabetic women, diabetic women had a 4.3-fold increase in AMI, 4.4-fold increase in PCI, and 6.2-fold increase in CABG admissions, supporting the notion that diabetic females have an elevated incidence of CVD risk factors, compared to diabetic men. Further, pre-menopausal women usually present with CVD almost a decade later than males; however, this protection is not seen in pre-menopausal women diagnosed with T2DM ([@B103]).

Considering unique sex-based differences in physiology and pathophysiology, it is worth noting some of the most apparent sex-specific factors that underlie our understanding of the above-mentioned observations. First, it has been documented that females have altered systemic glucose regulation, compared to males ([@B13]; [@B47]). For example, in one clinical study, it was shown that systemic insulin was higher after dextrose infusion in females, suggesting lower insulin-sensitivity at baseline in females compared to males ([@B47]). Second, pre-menopausal women demonstrate different fat distribution compared to men. In contrast to the central (visceral) adiposity observed in males, females tend to have peripheral fat distribution, contributing to higher insulin sensitivity at greater levels of body mass ([@B137]). Due to this, women typically have increased metabolic disturbances (body mass index and insulin resistance) before overt T2DM diagnosis and therefore incur higher CVD risk ([@B86]; [@B54]). Third, and possibly the most important, yet commonly misunderstood, is the role that estrogen-related signaling within the female myocardium plays in disease progression and/or protection. Finally, a strong correlation is reported between the leukocyte telomere length (LTL) shortening and increase in metabolic syndrome components in females ([@B32]). LTL shortening and low telomerase activity are shown to be associated with CVD, coronary artery disease, diabetes mellitus, cardiomyopathy, and all-cause mortality ([@B8]; [@B146]; [@B120]). It is noteworthy that while telomerase activity in cardiomyocytes decreases in men with aging, it increases in women ([@B83]; [@B73]). However, how T2DM modulates this effect in the heart tissues of women versus men is currently unclear.

Diabetic Cardiomyopathy and an Unresolved Definition
====================================================

Scientists and clinicians alike face challenges when studying the pathophysiology of diabetic cardiomyopathy. Diabetic cardiomyopathy commonly presents with one or more comorbidities known to exacerbate heart failure. Functionally, diabetic cardiomyopath*y* is characterized by diastolic dysfunction, defined as a defect in left ventricular relaxation leading to increased pressures and a subsequent impaired filling during diastole ([@B87]). In both type 1 (T1DM) and T2DM, diastolic dysfunction is largely considered a hallmark of diabetic cardiomyopathy, although some reports suggest that upon adjustment for comorbidities, diastolic dysfunction is not statistically significant ([@B135]; [@B50]). [@B129] demonstrated that along the continuum of diabetic patients, higher HbA~1c~ levels are associated with the severity of diastolic dysfunction, as measured by E/E′, a non-invasive estimate of left atrial filling pressure that independently predicts primary cardiac events.

In diabetes, diastolic function as assessed by E/A ratio and hemodynamics has been shown to prematurely deteriorate compared to healthy controls. The E/A ratio represents the ratio of the E wave (peak blood flow velocity in early diastole) to the A wave (peak blood flow velocity in late diastole) caused by atrial contraction. The filling pattern, where there is a reduction in the E/A ratio along with prolongation of the deceleration time of E, indicates impaired relaxation. E/A values measured in young (20--32 years of age) T1DM males match that of healthy men at 50 years of age, suggesting that T1DM negatively effects diastolic function ([@B17]). Two more recent reports ([@B71]; [@B131]) using echocardiography evaluation of T1DM patients without known CVD, reported the presence of diastolic dysfunction. Indeed, one study assessed adolescent T1DM patients (mean duration of disease = 6 years) and found, both at rest and during exercise, these patients had reduced diastolic function ([@B62]), evidenced by end diastolic volume ([@B66]). In contrast, various other reports suggest that in long-term T1DM patients, evidence for diastolic dysfunction is lacking ([@B148]; [@B113]), indicating that T1DM's ability to cause diastolic dysfunction may be a factor of duration of disease, age of onset, management, and/or environment. The deleterious effects of diabetes on myocardial parameters are not synonymous between patients with T1DM versus T2DM, adding to the vagueness of diabetic cardiomyopathy. For example, T1DM is mostly associated with hyperglycemia, oxidative stress, and resultant myocardial fibrosis and average patient population with T1DM is younger than that with T2DM (**Figure [1](#F1){ref-type="fig"}**). In contrast, T2DM is linked to hyperinsulinemia, insulin resistance, obesity, and cardiomyocyte hypertrophy ([@B87]).

![Progression of T1DM and T2DM and development of diabetic cardiomyopathy. **(A)** Illustrates how an immune mediated response in T1DM destroys beta cells within pancreatic islets, leading to hyperglycemia, resulting in cardiac damage which promotes the development of diabetic cardiomyopathy. **(B)** Shows how environmental influences (diet, inactivity) lead to insulin resistance, hyperinsulinemia, beta cell burnout, and subsequent dysregulation of glucose, leading to hyperglycemia, cardiac damage, and ultimately diabetic cardiomyopathy. Noteworthy is the arrow indicating the progression of diabetic cardiomyopathy and that it occurs and progresses uniquely in certain populations of individuals, namely male and females.](fphys-09-00453-g001){#F1}

A 2003 publication assessed the fact that T1DM patients may present with diabetic autonomic neuropathy (DAN), and hypothesized that this may account for diastolic and/or systolic dysfunction ([@B44]). Using radionuclide ventriculography, it was found that T1DM patients had reduced diastolic parameters, including atrial contribution to ventricular filling, peak filling rate, first third filling fraction, and time to peak filling, suggesting diastolic dysfunction ([@B44]). The lack of cardiac dysfunction in long-term T1DM patients may also be related to permanent treatment with exogenous insulin. Others have suggested that myocardial overload and increased peripheral resistance resultant from exogenous insulin may be responsible for the observed diastolic dysfunction, rather than being symptoms of diabetic cardiomyopathy ([@B66]). In summary, numerous reports support the fact that diastolic dysfunction is the defining characteristic of diabetic cardiomyopathy in both T1DM and T2DM patients. However, until additional long-term studies are performed, debate will continue until a universal definition is settled upon. **Figure [2](#F2){ref-type="fig"}** summarizes the evidence for and against the (current) understanding and existence of diabetic cardiomyopathy.

![Evidence for and against the existence of diabetic cardiomyopathy. Venn diagrams show the current evidence for (Panel **A**, green) and against (Panel **B**, red) the existence of diabetic cardiomyopathy, and how they relate to T1DM, T2DM, and/or both. Molecular/physiological mechanisms documented in rodent models include oxidative stress, glucotoxicity, lipotoxicity, metabolic inflexibility, cardiac fibrosis, and mitochondrial dysfunction ([@B21]; [@B121]; [@B66]). Diastolic dysfunction implies heart failure with either preserved (HFpEF) or reduced (HFrEF) ejection fraction. HF = heart failure, T1DM = type 2 diabetes, T2DM = type 2 diabetes, and LV = left ventricle. ^∗∗^Indicates possible sex difference documented in literature.](fphys-09-00453-g002){#F2}

Alternatively, when considering rodent models of T1DM, clinical data regarding diastolic dysfunction has been corroborated ([@B24]). On a cellular and molecular level, rodent models of diabetic cardiomyopathy have helped develop our understanding of myocardial alterations. Due to their resistance to atherosclerosis, they provide a good model to study the effects of diabetes on the myocardium, independent of peripheral complications ([@B123]). Through the use of rodent models, mechanisms underlying diabetic cardiomyopathy, including cardiac fibrosis, mitochondrial dysfunction, oxidative stress, lipotoxicity, and metabolic inflexibility have been identified ([@B121]).

Importantly, there are a few human studies that lend support to rodent findings, including mitochondrial dysfunction, fibrosis, oxidative stress, and metabolic inflexibility ([@B110]; [@B4]), suggesting that rodent models may be a sufficient means to study diabetic cardiomyopathy progression. For example, consistent with observations from diabetic rat models, intra-myocardial lipid accumulation is seen in the failing heart of diabetic patients. Moreover, intra-myocardial lipid accumulation in T2DM patients correlates with impaired cardiomyocyte contractility and their inability to adapt after myocardial infarction, a phenomenon seen in diabetic rats ([@B124]; [@B20]). It was also reported that in obese, insulin-resistant men, abnormal left ventricular energy metabolism is observed prior to structural and functional pathological remodeling in the heart ([@B108]).

Together, these data further the potential uniqueness of diabetic cardiomyopathy in different models and buttress the existence of inherent limitations when comparing between clinical (human) and pre-clinical (rodent) experimental data. One feature that has long been known and is under no debate is that cardiomyocytes experience a loss of metabolic flexibility in the face of chronically high glucose in animal models of diabetes ([@B30]; [@B130]). The consequence of this on the progression of diabetic cardiomyopathy is important, yet our understanding of how this contributes to fibrotic remodeling and diastolic dysfunction remains to be fully understood. In this context, [@B52] reported that metabolic inflexibility to glucose in humans with T2DM is mostly related to defective glucose transport. One theme common to rodent and human studies is the disparity for the inclusion of female subjects ([@B98]; [@B99]), resulting in a lack of data specific to sex differences and treatment options specific to females. The gender-specific differences in diabetic cardiomyopathy and its progression, at the level of the myocardium remain largely unknown. A purpose of this review is to highlight the known data on the human and animal literature interrogating molecular mechanisms and sex differences contributing to diabetic cardiomyopathy.

Contribution of Sex Hormones in Diabetic Cardiomyopathy
=======================================================

Testosterone is the primary male sex hormone responsible for maturation of sex organs, sperm production, and secondary sexual characteristics in males ([@B80]). It is well established that testosterone levels peak during the third decade of life ([@B57]), and then decline at a rate of 1--2% annually thereafter ([@B46]). Epidemiological studies have shown that low levels of testosterone associate with increased risk of CVD ([@B114]; [@B5]; [@B38]; [@B116]). Furthermore, one in three type-2 diabetic men are testosterone deficient, suggesting that low testosterone levels are associated with metabolic syndrome and T2DM ([@B128]). In a streptozotocin-induced model of T1DM using Sprague--Dawley rats, treatment with testosterone increased cardiac angiogenesis, highlighting the cardioprotective role of testosterone ([@B35]). Given the associations between testosterone, aging, CVD, and metabolic diseases such as T2DM, further explorations into the possible role that testosterone levels play in the progression of diabetic cardiomyopathy are warranted. There is a paucity of data describing the specific effects of low testosterone levels on the development/progression of diabetic cardiomyopathy in males, or the underlying molecular and cellular mechanisms.

Estrogen, along with progesterone, are two female sexual-reproductive hormones that are precisely regulated throughout the life course. Estrogens (estrone, estriol, and the biologically active 17β-estradiol) are derived from cholesterol and produced via aromatization of androgens. Females, by virtue of higher estrogen levels, compared to males, have higher protection during pre-menopausal years on various organ systems, including cardiovascular and others ([@B77]; [@B94]). However, these protective effects are attenuated, and often times lost, when estrogen levels drop off significantly at the onset of menopause. In pre-menopausal women, serum estrogen concentrations range from 367 pmol per liter to 2200 pmol per liter. Upon menopause, these levels decrease significantly to between 18 and 74 pmol per liter, analogous to levels in similarly aged men ([@B147]). Free estrogen in the circulation binds to one of two receptors, estrogen receptor alpha (ER~α~) and estrogen receptor beta (ER~β~), both of which vary in expression depending on tissue type and age ([@B102]; [@B134]).

In addition to binding to its own receptor and subsequent intracellular signaling, estrogen can affect various physiological functions, not limited to serum lipid concentrations, antioxidant systems, nitric oxide (NO) production, and coagulation pathways ([@B96]). Estrogen has rapid effects (non-genomic), such as increased NO production and vasodilation, as well as long-term effects (genomic), including decreased atherosclerosis, vascular injury, smooth muscle growth, and increased endothelial cell growth and smooth muscle differentiation ([@B96]; [@B143]). Endothelial and vascular smooth muscle cells both express estrogen receptors. Endothelial cells are the first line of defense against any foreign substance that remains in the blood stream and may contribute to vascular disease ([@B76]; [@B133]; [@B53]). *In vitro*, estrogen is capable of increasing NO release from endothelial cells rapidly, prior to any changes in gene expression ([@B28]; [@B81]). Released NO signals to the vascular smooth muscle cells (VSMCs) to relax, contributing to vasodilation and inhibiting platelet activation ([@B16]; [@B119]). Endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS), responsible for synthesizing NO, have also been shown to be regulated by endogenous estrogen levels. This suggests that the primary mediators of vascular tone, NOS and NO, are involved in the dysregulation and/or increased protective effects in both males and females, during the development of diabetic cardiomyopathy ([@B138]), but are likely to play a more significant role in females. A New England Journal of Medicine article concludes "Direct myocardial effects of estrogen on cardiac structure and function are likely to be important as well and deserve greater attention" ([@B96]). In female rats, the absence of estrogen is associated with left ventricular hypertrophy, collagen deposition, and increased sensitivity to angiotensin II ([@B144]; [@B42]). Estrogen offers protection to cardiomyocytes via prevention of apoptosis and reduced infarct size ([@B106]; [@B107]; [@B79]).

Considering that one hallmark characteristic of diabetic cardiomyopathy is damage to the myocardium in the absence of atherosclerosis or peripheral artery disease, it is important to realize the effects of estrogen on the myocardium and cardiomyocytes. With the onset of menopause, and subsequent decrease in estrogen levels, many women begin hormone replacement therapy (HRT) in order to maintain higher physiological levels of estrogens. While this is not without side effects \[see reviews for HRT negative consequences ([@B145])\], evidence from both prospective and retrospective observational studies show that HRT offers protection from CVD in previously healthy women by 35--50% ([@B56]; [@B95]; [@B59], [@B58]; [@B11]; [@B70]). What is less clear are the many interactions between low levels of estrogen, CVD, and existing T2DM, and if HRT provides protection from diabetic cardiomyopathy in longstanding diabetics. Attempts to tease out the specific underlying mechanisms, whereby chronically high glucose damages the myocardium and the role estrogen may play in preventing this in females remain in their infancy and require further attention.

Oxidative Stress and Diabetic Cardiomyopathy
============================================

Cardiac oxidative stress is thought to be one of the primary insults leading to subsequent fibrosis, apoptosis, cellular damage, and hypertrophy ([@B67]). One study examined 12-week-old female Sprague--Dawley rats after induction of T1DM using Alloxan and reported that markers of oxidative stress were dysregulated in diabetic animals compared to age-matched control rats. The authors suggest that in their model, Alloxan-induced diabetes caused cardiomyopathic changes, and these changes are likely mediated by oxidative stress ([@B2]). Additional studies have documented the association between oxidative stress and T1DM-induced cardiac damage ([@B149]). Similarly, pre-clinical models of T2DM have been used to assess the role of oxidative stress in the progression of diabetic cardiomyopathy, with several transgenic, and diet-induced models suggesting a strong connection between diabetic cardiomyopathy and oxidative stress ([@B150]; [@B25]; [@B51]; [@B36]). Evidence suggests that oxidative stress exhibits sex differences. For example, superoxide dismutase activity was found to be higher in female rat heart compared to male rat heart indicating that oxidative stress is lower in female rat heart compared to male rat heart ([@B10]). In humans, *in vivo* biomarkers of oxidative stress are reported to be higher in young men than in women of the same age ([@B69]). Furthermore, reactive oxygen species (ROS) production in the vascular cells from males are higher than cells from females ([@B92]). Sex differences in oxidative stress are also seen in healthy term neonates and their mothers ([@B43]). Female-specific reduced systemic oxidative stress may play a role in improved cardio-protection in healthy females compared to males.

Studies in db/db mice show that while both males and females exhibited age-associated increases in the left ventricular atherosclerosis biomarker, plasminogen activator inhibitor 1 (PAI-1), females had a marked increase as diabetes progressed, compared to males, indicating a possible role for PAI-1 in diabetic cardiomyopathy ([@B152]; [@B23]). [@B23] demonstrated that many of the deleterious diabetic complications were exacerbated in female db/db mice compared to their male counterparts, lending support to the hypothesis that diabetic women are more susceptible to diabetic cardiomyopathy ([@B109]). Surprisingly, LV fibrosis and SERCA2a expression were higher in diabetic mice, compared to controls, but did not show a sex-specific effect. However, in these same animals, oxidative stress was greater in db/db females compared to males ([@B23]).

Cardiac fibrosis, which occurs as a by-product of oxidative stress, is a hallmark feature of CVD. In the diabetic heart, fibrosis has been documented to progress in the left ventricle as a result of increased expression and presence of collagens and other extracellular matrix proteins, which stiffens the ventricular walls ([@B142]; [@B7]; [@B68]). As a result, it is common for compensatory left ventricular hypertrophy to occur due to the heart attempting to compensate for increased stiffness. Clinical studies using cardiovascular magnetic resonance have shown significant sex differences in left ventricular remodeling and myocardial fibrosis among patients with heart disease and women show higher New York Heart Association (NYHA) class and greater left ventricular remodeling index ([@B31]; [@B84]). The population of patients in this study included similar numbers of male and female patients with diabetes. Another study showed that women have higher levels of fibrosis than men among patients with long-standing persistent atrial fibrillation ([@B84]).

Human Data Supporting Sex Differences in Diabetic Cardiomyopathy
================================================================

The rates of T2DM incidence are roughly 6.6 and 5.9% of the population for men and women, respectively ([@B29]). Interestingly, diabetic cardiomyopathy incidence remains higher in diabetic females compared to diabetic males, and this is further complicated by the pre- and post-menopausal stages of women and the vital role that estrogen may be playing in disease protection and progression. A 2014 meta-analysis that analyzed 64 cohorts, including 858, 506 individuals, and 28,203 cardiac events, concluded that diabetic women have a 40% greater risk of incident coronary heart disease compared with diabetic men ([@B109]). Note that most of the studies to date focus on coronary heart disease rather than diabetic cardiomyopathy -- implying that the participants were not free from peripheral disease, including hypertension, coronary artery disease and/or atherosclerosis. This is due to the absence of large cohort studies specifically looking at diabetic cardiomyopathy and sex differences. Additionally, virtually no large-scale human studies have inquired specifically into any mechanistic understanding of diabetic cardiomyopathy and the role that sex and sex hormones play.

A 2015 population-based survey examined 2,042 randomly selected residents in Minnesota, aged 45 years or older ([@B40]). Participants underwent initial echocardiographic assessment of systolic and diastolic function and were followed for 3 years. It was reported that the incidence of diabetic cardiomyopathy in diabetic patients in this cohort was 16.9% and the prevalence of diastolic dysfunction was 54%. Indeed, the authors demonstrated that diabetic cardiomyopathy is associated with a high cumulative probability of the development of heart failure and death. The authors concluded that diabetic cardiomyopathy is relatively common in the studied community and that morbidity and mortality in patients with diabetic cardiomyopathy is high, reaching 31% in the studied population. Notably, this survey did not look at the differences between males and females, and more specifically, the role that sex hormones play in the incidence and progression of diabetic cardiomyopathy.

The Rancho Bernardo Study is a prospective population-based study of older adult inhabitants of Southern California. Subjects were recruited and monitored yearly with questionnaires and every 4 years by clinical evaluation. The study evaluated both male and female T2DM patients for 14 years and, among other outcome measures, concluded that "diabetes in women overrides their natural advantages and that is not entirely\...mediated by many other conventional heart disease risk factors." One aspect of this natural advantage that they discuss is the levels of high-density lipoprotein cholesterol (HDLC) being lower in diabetic women compared with both healthy women and diabetic men ([@B12]). Furthermore, data suggests that HDLC at normal or elevated levels confers more protection in women than men ([@B39]; [@B55]).

Rodent Data Supporting Sex Differences in Diabetic Cardiomyopathy
=================================================================

Our understanding of diabetic cardiomyopathy incidence in humans has largely been a result of the previously mentioned epidemiological and cross-sectional studies, and meta-analysis. However, the current understanding of diabetic cardiomyopathy progression and the mechanisms involved are largely a result of pre-clinical rodent studies. Several experimental rodent models have been developed to study various contributing factors to diabetic cardiomyopathy; including several genetically modified models; db/db mice, ob/ob mice, Otsuka Long-Evans Tokushima (OLETF) rats, CIRKO (cardiomyocyte deletion of insulin receptor) mice, cardiac lipotoxic mice \[cardiomyocyte-specific long-chain acyl-CoA synthetase (ACS) and fatty acid transport protein (FATP1) overexpressing\], Zucker diabetic fatty (ZDF), Zucker obese (ZO), lean (ZL) rats, and various other diet-induced obesity (DIO) strains. Monogenic, polygenic, and pharmacologically altered rodent models all provide insight into disease progression but are not without challenges when comparing back to human disease. Indeed, human diabetic cardiomyopathy is the result of a sequence of deleterious events that occur in succession, leading to eventual cardiac dysfunction in diabetic patients. The mechanisms elucidated from rodents and currently thought to be responsible for diabetic cardiomyopathy progression include: increased myocardial lipotoxicity, hypertrophy, decreased cardiac function, altered cytokine profile, increased oxidative stress, interstitial fibrosis, contractile and mitochondrial dysfunction, and altered myocardial metabolism.

The db/db and ob/ob genetic mouse models, both of which have altered leptin signaling and become obese, insulin-resistant and mild to severely hyperglycemic, provide a useful model to look at the damaging effects of diabetes on the myocardium. Noteworthy, few studies have included both males and females in an attempt to understand sex differences in these models. The db/db mice myocardium is characterized by increased oxidative stress, \[([@B22]) male mice\], cardiomyocyte apoptosis ([@B9]), diastolic dysfunction \[([@B122]) -- male mice\], and mitochondrial ROS \[([@B22]) -- male mice\]. Isolated db/db hearts exhibit decreased left ventricular function compared to ob/ob hearts ([@B93]; [@B63]). Indeed, ob/ob mice have a reduction in 'cardiac metabolic flexibility,' meaning that in times of stress, i.e., hypoxia or ischemia, when a healthy heart would switch from fatty acids to glucose for fuel, obese ob/ob hearts are unable to switch substrate utilization ([@B21]). Cardiac metabolism in db/db and ob/ob mouse models demonstrate decreased glucose oxidation and increased fatty acid oxidation. Indeed, this attenuation of metabolic flexibility increases the risk of ischemic damage and associates with insulin resistance and reductions in mitochondrial oxidative capacity.

The male ZDF rat has been extensively used as a rodent model of hyperglycemia and T2DM. Young ZDF-male rats exhibit severe hyperglycemia, diastolic dysfunction with preserved ejection fraction, reduced cardiac capillary density and cardiac structural damage caused by fibrosis and mitochondrial disorganization ([@B14]; [@B111]). Diabetic cardiomyopathy in young hyperglycemic ZDF-female rats shares the features of reduced capillary density and mitochondrial damage with ZDF-male rats ([@B90]). However, ZDF-female rats did not exhibit cardiac fibrosis, but demonstrated increase in heart weight and cardiomyocyte hypertrophy and higher levels of phosphorylation of cardiac mTOR (mechanistic target of rapamycin).

Myocardial contractility and structural parameters of the heart are different between male and female rats. Specifically, cardiomyocytes from male Wistar rats exhibit hypertrophy and undergo a greater degree of postnatal growth compared to female rats ([@B27]). Similarly, 5-month-old ZL-male rats have larger hearts compared to ZL-female rats. Presence of T2DM is associated with increased risk of left ventricular hypertrophy, however, prolonged T2DM and severe hyperglycemia causes muscle loss. The 5-month-old ZDF-female rats that exhibited both hyperinsulinemia and hyperglycemia showed a greater degree of hypertrophy, both in terms of cardiomyocyte size and total heart size (adjusted to tibia length), compared to their lean counterparts, whereas age-matched ZDF male rats that had prolonged hyperglycemia did not show cardiac hypertrophy ([@B90]). [@B19] have compared the sexual dimorphism in human and rodent cardiovascular physiology in a recent review.

Previous studies have shown that there is a pan suppression of intracardiac cytokines in another T2DM rat model, the ZO-male rat ([@B89]). The ZO-male rat also has a mutation in the leptin receptor and is characterized by obesity, hyperinsulinemia, mild hyperglycemia, diastolic dysfunction with preserved ejection fraction, cardiac hypertrophy, and fibrosis ([@B61]; [@B89]). Compared to ZL-males, both ZO-male and ZDF-male rats exhibited a suppression of GM-CSF, IL-10, and IFN-γ ([@B89]; [@B90]). GM-CSF, IL-10 ([@B140]; [@B125]), and IFN-γ ([@B105]; [@B45]) are anti-fibrotic cytokines and their suppression could have contributed to cardiac fibrosis in these male T2DM models. Conversely, expression of these anti-fibrotic intracardiac cytokines was comparable between ZDF-female rats and ZL-female rats. This sex difference in the expression of anti-fibrotic intracardiac cytokines may be one of the reasons underlying the sex differences in diabetic cardiomyopathy (**Figure [3](#F3){ref-type="fig"}**). Interestingly, suppression of neuropilin-1, associated with increased cardiomyopathy ([@B136]), was observed in healthy females compared to male rats and also in diabetic rats of both sexes, compared to their healthy counterparts. This observation suggests that reduction in neuropilin-1 is an important contributor to diabetic cardiomyopathy.

![Sex differences in cardiomyocytes between healthy and diabetic cardiomyopathy. **(A)** Diagram of a male cardiomyocyte as it progresses from healthy to diabetic cardiomyopathy. In male, mTORC1 activation and hypertrophy are observed in some models but not others (indicated by dashed outer cardiomyocyte outline), while AT2R expression is not changed. While fatty acid (FA) uptake, fibrosis, collagen 1a, and miR-29a/b/c/ are increased with disease progression, the following are all reduced with disease progression; FA utilization, capillary density, mitochondrial function, and *Med13*-signaling, and several cytokines including IL-2, IL-10, IFN-γ, and GM-CSF. **(B)** Diagram of a female cardiomyocyte as it progresses from healthy to diabetic cardiomyopathy. In the female, mTORC1 activation and hypertrophy are observed. Additionally, miR-208a and miR-29a/b/c are increased, while FA utilization, mitochondrial function, fibrosis, *Agtr2-Med13* signaling, capillary density, collagen 1a, and NRP-1 are decreased ([@B139]; [@B97]; [@B121]; [@B90]).](fphys-09-00453-g003){#F3}

Noteworthy is the sex difference in young ZDF-males and females in regards to DIO and T2DM ([@B100]). ZDF-males develop hyperinsulinemia, hyperglycemia, and T2DM on standard chow. ZDF-females require a high fat diet with 48 kcal% Lard (Diet \#12468 formulated by Edward A. Ulman, Ph.D. Research Diets, Inc.), in order to induce metabolic disease and T2DM. Thus, ZDF females need an additional insult, a high fat diet to induce T2DM. Importantly, this leads to the speculation that, in this model, females possess some level of "protection" and with it, an ability to delay hyperglycemia, hyperinsulinemia, and T2DM. Interestingly, the effect of DIO on the onset of T2DM differs also in mice and this effect depends on the age at which the high fat diet is started. In juvenile mice, DIO induces T2DM in males, but not in females ([@B117]). However, if the DIO is initiated in adult mice, this sex difference in the induction of T2DM disappears.

Unlike the above rodent models that are characterized by systemic metabolic disruption, other models have been created that are cardiac specific and allow the deleterious effects of prolonged diabetes to be produced quickly in cardiac tissue. These models include CIRKO mice and cardiac lipotoxic mice (ACS and FATP1 overexpressing). The CIRKO mouse was first characterized in 2002 and provided a model that separated the intrinsic defects in cardiomyocytes from the potential confounding effects of altered systemic hyperglycemia ([@B15]). Similar to the CIRKO mouse, models of cardiac myocyte-specific liptoxicity provide an alternative lens to look at how fatty acid accumulation damages the heart muscle independent of peripheral and systemic disturbances. There have been two models developed that rely on excess fat entry into cardiomyocytes, mimicking severe diabetic cardiomyopathies. These models include cardiomyocyte-specific ACS and FATP1 overexpressing mice ([@B34], [@B33]). The resultant pathology exhibited large increases in fatty acids within the myocardium, and therefore, many of the deleterious effects on cardiac function are seen as in diabetic cardiomyopathy. These perturbations in lipid homeostasis within cardiomyocytes offers an experimental model to recapitulate the negative cellular effects commonly observed in clinical diabetic cardiomyopathy. However, these studies did not explore how biological sex differences modulate cardiac pathology of these models.

Emerging Molecular Markers of Sex Differences in Diabetic Cardiomyopathy
========================================================================

Given the uniqueness of the molecular signature of diabetic cardiomyopathy, development and understanding of the targets and specific sex differences remains a vitally important area of inquiry. One of the molecules that regulates cardiac conduction and hypertrophy is the microRNA (miRNA) miR-208a ([@B26]). Interestingly, miR-208a exhibits sex differences, with expression being higher in the heart tissues of ZL-female rats compared to ZL-male rats ([@B90]). T2DM increased miR-208a expression in both ZDF-male and ZDF-female hearts, resulting in ZDF-females having the highest expression. Thus miR-208a is a miRNA that links T2DM and cardiac dysfunction and hypertrophy. Notably, *ex vivo* studies on mouse aorta showed that miR-208a was suppressed by estrogen ([@B151]). However, in healthy female rats with intact ovary, cardiac miR-208a expression was higher than that seen in males, indicating that estrogen-mediated regulation of miR-208a *in vivo* is different. A recent review by [@B48] discusses sex bias in miRNA expression and its correlation with the higher prevalence of heart failure with preserved ejection fraction (HFpEF) in women. HFpEF is a hall mark of diabetic cardiomyopathy. Pre-clinical studies in healthy mice and *in vitro* studies using estrogen have identified miRNAs either regulated by estrogen (miR-203, miR-126, miR-23a, miR-21, miR-24, miR-27a and b, and miR-106a and b) or encoded by X-chromosome (miR-98, miR-652, miR-221, miR-222, miR-223, miR-361, miR-421, miR-325, miR-188, miR-92a, miR-424, miR-503, miR-505). Authors suggest that estrogen-mediated regulation and/or link to X-chromosome play a role in sex bias of these miRNAs that contribute to CVD ([@B48]).

Cardiac Mediator Complex 13 (MED13), encoded by the *Med13* gene, plays a critical role in systemic energy homeostasis and confers resistance to weight gain ([@B60]). MED13 also improves systemic insulin sensitivity and glucose tolerance and is increased by treatment with mTOR complex 1 inhibitors rapamycin and nebivolol ([@B61]). Heart tissues of ZL-females exhibit higher levels of *Med13* mRNA compared to ZL-male rats, indicating that MED13 is a molecule that may provide increased cardioprotection in healthy female rat hearts. *Med13* mRNA is an established target of miR-208a ([@B60]; [@B61]). T2DM suppressed cardiac *Med13* mRNA levels in both sexes, which is consistent with the T2DM-induced increase in miR-208a. Notably, both miR-208a and *Med13* expression levels were higher in ZL-female rats, indicating that in healthy female rats, other mechanisms contributed to increased expression of *Med13*; however, this advantage was lost in diabetic ZDF-female rats.

Angiotensin II type 2 receptor (AT2R), encoded by the X-linked *Agtr2* gene, has been documented to confer cardiovascular protective and reparative effects. Activating AT2R signaling by agonists and increasing *Agtr2* gene copy number by genetic manipulation in murine models improves cardiac repair and enhances cardiac function ([@B3]; [@B112]; [@B127]). AT2R exhibits sex differences in cardiovascular expression ([@B104]; [@B118]; [@B65]; [@B90]). AT2R expression is higher in the vasculature of healthy murine female models. This female-specific increased AT2R expression contributes to their increased resistance to hypertension and protection from cardiovascular and renal injury compared to males.

Conclusion and Future Directions
================================

The NIH ([@B37]) has long recognized sex disparities in human clinical trials as a problem, and in 1993, passed the NIH Revitalization Act. In the 2 decades since, over half of NIH-funded clinical research participants are now women. The area that is still experiencing sex bias are pre-clinical studies, including *in vitro* and *in vivo* studies. In fact, a 2010 Nature opinion article shows that males still dominate animal studies ([@B153]). Based on current trends, diabetes incidence will continue to increase and with it the co-morbidities, such as obesity, hypertension, and diabetic cardiomyopathy. Given the unique sex differences observed between males and females, future work needs to be aimed at understanding the role of sex-specificity on the progression of diabetic cardiomyopathy. There is desperately the need for a push for possible unique therapeutic treatment options that will address sex differences. Pre-clinical models can continue to help identify, test, and optimize possible therapies, with the hopes to make the leap into human trials. Paramount to this is the need for a continued scientific and medical discussion and elucidation of an agreed upon clinical definition of diabetic cardiomyopathy. Although the role of estrogen-mediated signaling in better cardiovascular protection of healthy females compared to males is well established, this female advantage is lost in T2DM and diabetic cardiomyopathy. Therefore, identifying additional therapeutic targets to improve cardiovascular outcomes of diabetic females is a critical need. AT2R and MED13 are cardioprotective molecules that exhibit female-specific increased expression in rodent studies. Moreover, currently there are no AT2R agonists in clinic to treat heart disease. Developing drugs that can increase expression of MED13 and AT2R in diabetic heart can lead to better treatment paradigms for diabetic cardiomyopathy and to mitigate sex differences in this pathology.
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